Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Evaluating the influence of common antibiotics on the efficacy of a recombinant immunotoxin in tissue culture.

Zhu Y, Weldon JE.

BMC Res Notes. 2019 May 27;12(1):293. doi: 10.1186/s13104-019-4337-6.

2.

Investigation of amino acid specificity in the CydX small protein shows sequence plasticity at the functional level.

Hobson JJ, Gallegos AS, Atha BW 3rd, Kelly JP, Lein CD, VanOrsdel CE, Weldon JE, Hemm MR.

PLoS One. 2018 Jun 18;13(6):e0198699. doi: 10.1371/journal.pone.0198699. eCollection 2018.

3.

Designing the furin-cleavable linker in recombinant immunotoxins based on Pseudomonas exotoxin A.

Weldon JE, Skarzynski M, Therres JA, Ostovitz JR, Zhou H, Kreitman RJ, Pastan I.

Bioconjug Chem. 2015 Jun 17;26(6):1120-8. doi: 10.1021/acs.bioconjchem.5b00190. Epub 2015 Jun 3.

PMID:
25997032
4.

Identification and elimination of an immunodominant T-cell epitope in recombinant immunotoxins based on Pseudomonas exotoxin A.

Mazor R, Vassall AN, Eberle JA, Beers R, Weldon JE, Venzon DJ, Tsang KY, Benhar I, Pastan I.

Proc Natl Acad Sci U S A. 2012 Dec 18;109(51):E3597-603. doi: 10.1073/pnas.1218138109. Epub 2012 Dec 3.

5.

A recombinant immunotoxin against the tumor-associated antigen mesothelin reengineered for high activity, low off-target toxicity, and reduced antigenicity.

Weldon JE, Xiang L, Zhang J, Beers R, Walker DA, Onda M, Hassan R, Pastan I.

Mol Cancer Ther. 2013 Jan;12(1):48-57. doi: 10.1158/1535-7163.MCT-12-0336. Epub 2012 Nov 6.

6.

A recombinant immunotoxin engineered for increased stability by adding a disulfide bond has decreased immunogenicity.

Liu W, Onda M, Kim C, Xiang L, Weldon JE, Lee B, Pastan I.

Protein Eng Des Sel. 2012 Jan;25(1):1-6. doi: 10.1093/protein/gzr053. Epub 2011 Nov 17.

7.

A guide to taming a toxin--recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer.

Weldon JE, Pastan I.

FEBS J. 2011 Dec;278(23):4683-700. doi: 10.1111/j.1742-4658.2011.08182.x. Epub 2011 Jun 2. Review.

8.

Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopes.

Onda M, Beers R, Xiang L, Lee B, Weldon JE, Kreitman RJ, Pastan I.

Proc Natl Acad Sci U S A. 2011 Apr 5;108(14):5742-7. doi: 10.1073/pnas.1102746108. Epub 2011 Mar 21.

9.

A recombinant immunotoxin targeting CD22 with low immunogenicity, low nonspecific toxicity, and high antitumor activity in mice.

Hansen JK, Weldon JE, Xiang L, Beers R, Onda M, Pastan I.

J Immunother. 2010 Apr;33(3):297-304. doi: 10.1097/CJI.0b013e3181cd1164.

PMID:
20445350
10.

A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity.

Weldon JE, Xiang L, Chertov O, Margulies I, Kreitman RJ, FitzGerald DJ, Pastan I.

Blood. 2009 Apr 16;113(16):3792-800. doi: 10.1182/blood-2008-08-173195. Epub 2008 Nov 6.

11.

Pigment epithelium-derived factor binds to hyaluronan. Mapping of a hyaluronan binding site.

Becerra SP, Perez-Mediavilla LA, Weldon JE, Locatelli-Hoops S, Senanayake P, Notari L, Notario V, Hollyfield JG.

J Biol Chem. 2008 Nov 28;283(48):33310-20. doi: 10.1074/jbc.M801287200. Epub 2008 Sep 19.

12.

Structure and properties of a truely apo form of AraC dimerization domain.

Weldon JE, Rodgers ME, Larkin C, Schleif RF.

Proteins. 2007 Feb 15;66(3):646-54.

PMID:
17173282
13.
14.
15.

The gene ygdP, associated with the invasiveness of Escherichia coli K1, designates a Nudix hydrolase, Orf176, active on adenosine (5')-pentaphospho-(5')-adenosine (Ap5A).

Bessman MJ, Walsh JD, Dunn CA, Swaminathan J, Weldon JE, Shen J.

J Biol Chem. 2001 Oct 12;276(41):37834-8. Epub 2001 Jul 30.

Supplemental Content

Loading ...
Support Center